A team of Columbia scientists is examining patient samples and experimenting with organoids to understand why colon cancer is on the rise in people under 50.
Having a rapport with kids is a critical part of the job for James Church and other Columbia colorectal surgeons who treat people with hereditary colon cancer.
Researchers have identified a biomarker that predicts which stage II colon cancer patients may benefit from adjuvant chemotherapy to prevent a disease recurrence.
Dr. Ravi P. Kiran has been named chief and program director of the Division of Colorectal Surgery at NewYork-Presbyterian/Columbia University Medical Center.